Publications and communications of Ehx, Grégory

Ruiz, M. V., Apavaloaei, A., Zhao, Q., Hardy, M.-P., Lemieux, S., Perreault, C., & Ehx, G. (August 2021). BamQuery: A new proteogenomic tool to explore the immunopeptidome and validate tumor‐specific antigens. European Journal of Immunology, 51 (S1), 60. doi:10.1002/eji.202170200

Canti, L.* , Humblet-Baron, S.* , Desombere, I., Neumann, J., Pannus, P., Heyndrickx, L., Henry, A., SERVAIS, S., WILLEMS, E., Ehx, G., Goriely, S., Seidel, L., Michiels, J., Willems, B., Liston, A., Ariën, K. K., Beguin, Y., Goossens, M. E., Marchant, A., & Baron, F. (2021). Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients. Journal of hematology & oncology, 14 (1), 174. doi:10.1186/s13045-021-01190-3

Courtois, J., Ritacco, C., DUBOIS, S., Canti, L., Vandenhove, B., SEIDEL, L., Daulne, C., CAERS, J., SERVAIS, S., Beguin, Y., Ehx, G., & BARON, F. (2021). Itacitinib prevents xenogeneic GVHD in humanized mice. Bone Marrow Transplantation, 56, 2672-2681. doi:10.1038/s41409-021-01363-1

Ehx, G., Ritacco, C., HANNON, M., DUBOIS, S., Delens, L., WILLEMS, E., SERVAIS, S., Drion, P., BEGUIN, Y., & Baron, F. (2021). Comprehensive analysis of the immunomodulatory effects of rapamycin on human T cells in graft-versus-host disease prophylaxis. American Journal of Transplantation, 21, 2662-2674. doi:10.1111/ajt.16505

Ritacco, C., Ehx, G., GREGOIRE, C., Daulne, C., WILLEMS, E., SERVAIS, S., BEGUIN, Y., & Baron, F. (2021). High proportion of terminally-differentiated regulatory T cells after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 56, 1828-1841. doi:10.1038/s41409-021-01221-0

Bolomsky, A., Vogler, M., Köse, M. C., Heckman, C. A., Ehx, G., Ludwig, H., & Caers, J. (2020). MCL-1 inhibitors, fast-lane development of a new class of anti-cancer agents. Journal of hematology & oncology, 13 (1), 173. doi:10.1186/s13045-020-01007-9

Delens, L., Ehx, G., SOMJA, J., Vrancken, L., Belle, L., SEIDEL, L., Grégoire, C., Fransolet, G., Ritacco, C., Hannon, M., DUBOIS, S., Beguin, Y., Baron, F., & Servais, S. (2019). In Vitro Th17-Polarized Human CD4(+) T Cells Exacerbate Xenogeneic Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 25, 204-215. doi:10.1016/j.bbmt.2018.10.007

Grégoire, C., Ritacco, C., Hannon, M., SEIDEL, L., Delens, L., Belle, L., DUBOIS, S., Veriter, S., LECHANTEUR, C., BRIQUET, A., Servais, S., Ehx, G., Beguin, Y., & Baron, F. (2019). Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model. Frontiers in Immunology, 10, 619. doi:10.3389/fimmu.2019.00619

Ehx, G., SOMJA, J., Warnatz, H.-J., Ritacco, C., HANNON, M., Delens, L., Fransolet, G., DELVENNE, P., Muller, J., BEGUIN, Y., Lehrach, H., Belle, L., Humblet-Baron, S., & BARON, F. (2018). Xenogeneic graft-versus-host disease in humanized NSG and NSG-HLA-A2/HHD mice. Frontiers in Immunology, 9, 1943. doi:10.3389/fimmu.2018.01943

Ehx, G., Fransolet, G., De Leval, L., D'Hondt, S., Lucas, S., Hannon, M., Delens, L., DUBOIS, S., Drion, P., Beguin, Y., Humblet-Baron, S., & Baron, F. (2017). Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. Oncoimmunology, 6:e1314425. doi:10.1080/2162402X.2017.1314425

Belle, L.* , Fransolet, G.* , Somja, J., BINSFELD, M., Delvenne, P., Drion, P., Hannon, M., BEGUIN, Y., Ehx, G.* , & Baron, F.*. (12 December 2016). Limited Impact of Imatinib in a Murine Model of Sclerodermatous Chronic Graft-versus-Host Disease. PLoS ONE, 11, 0167997. doi:10.1371/journal.pone.0167997

Fransolet, G.* , Ehx, G.* , SOMJA, J., Delens, L., Hannon, M., Muller, J., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., DELVENNE, P., BEGUIN, Y., Conteduca, G.* , & BARON, F.*. (04 July 2016). Azacytidine mitigates experimental sclerodermic chronic graft-versus-host disease. Journal of Hematology and Oncology, 9, 53. doi:10.1186/s13045-016-0281-2

SERVAIS, S., BEGUIN, Y., Delens, L., Ehx, G., Fransolet, G., Hannon, M., WILLEMS, E., Humblet-Baron, S., Belle, L., & Baron, F. (11 May 2016). Novel approaches for preventing acute graftversus- host disease after allogeneic hematopoietic stem cell transplantation. Expert Opinion on Investigational Drugs, 9, 957-972. doi:10.1080/13543784.2016.1182498

Göktuna, S., Shostak, K., Chau, T.-L., Heukamp, L., Hennuy, B., Duong, H. Q., LADANG, A., Close, P., Klevernic, I., Olivier, F., Florin, A., Ehx, G., Baron, F., Vandereyken, M., Rahmouni, S., Vereecke, L., van Loo, G., Büttner, R., Greten, F., & Chariot, A. (2016). The Prosurvival IKK-Related Kinase IKK« Integrates LPS and IL17A Signaling Cascades to Promote Wnt-Dependent Tumor Development in the Intestine. Cancer Research, 76, 2587-99. doi:10.1158/0008-5472.CAN-15-1473

Fransolet, G., Ehx, G., SOMJA, J., Hannon, M., DUBOIS, S., Drion, P., CAERS, J., Humblet-Baron, S., Belle, L., Delvenne, P., BEGUIN, Y., Conteduca, G., & Baron, F. (19 November 2015). L'Azacytidine comme traitement de la maladie du greffon contre l'hôte de type chronique sclérodermique expérimentale. Paper presented at 15ème congrès de la Société Française de Greffe de Moelle et de Thérapie Cellulaire, Clermont-Ferrand, France.

HANNON, M., BEGUIN, Y., Ehx, G., SERVAIS, S., SEIDEL, L., Graux, C., Maertens, J., Kerre, T., Daulne, C., de Bock, M., Fillet, M., ORY, A., WILLEMS, E., GOTHOT, A., Humblet-Baron, S., & BARON, F. (15 July 2015). Immune Recovery after Allogeneic Hematopoietic Stem Cell Transplantation following Flu-TBI versus TLI-ATG Conditioning. Clinical Cancer Research, 21 (14), 3131-9. doi:10.1158/1078-0432.CCR-14-3374

Fransolet, G., Ehx, G., SOMJA, J., Belle, L., Drion, P., Humblet-Baron, S., Beguin, Y., & Baron, F. (30 January 2015). Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease. Poster session presented at 30th general annual meeting of the Belgian Hematological Society, La Hulpe, Belgium.

Ehx, G.* , Hannon, M.* , BEGUIN, Y., Humblet-Baron, S.* , & BARON, F.*. (2015). Validation of a multicolor staining to monitor phosphoSTAT5 levels in regulatory T-cell subsets. Oncotarget, 6, 43255-43266. doi:10.18632/oncotarget.6486

Ehx, G.* , Gerin, S.* , Mathy, G., Franck, F., Oliveira, H. C., Vercesi, A. E., & Sluse, F. (21 July 2014). Liver proteomic response to hypertriglyceridemia in human-apolipoprotein C-III transgenic mice at cellular and mitochondrial compartment levels. Lipids in Health and Disease, 13, 116. doi:10.1186/1476-511X-13-116

Baron, F., Humblet-Baron, S., Ehx, G., SERVAIS, S., HANNON, M., Belle, L., LECHANTEUR, C., BRIQUET, A., GIET, O., BAUDOUX, E., WILLEMS, E., & Beguin, Y. (2014). Thinking out of the box - New approaches to controlling GVHD. Current Hematologic Malignancy Reports, 9, 73-84. doi:10.1007/s11899-013-0187-9